Clinical Experience with Telavancin for the Treatment of Patients with Bacteremia and Endocarditis: Preliminary Results from the Telavancin Observational Use Registry (TOUR™)

Joseph Reilly, Micah A. Jacobs², Asma La³, Anna Osmukhina², Bibiana Castaneda-Ruiz²

Coastal Infectious Disease Consultants, LLC, Pomona, NJ, USA; Romani, Pontizer & Associates, Pittsburgh, PA, USA; TheravanceBiopharma US, Inc., South San Francisco, CA, USA

INTRODUCTION

TOUR™ is a prospective, non-interventional study designed to evaluate the use of Telavancin in real-world clinical practice in patients with bacteremia and endocarditis. The study was established to gather clinical and safety data from patients treated with Telavancin who are representative of real-world clinical practice. The study is sponsored by Theravance Biopharma, Inc., who conducted this study.

METHODS

TOUR™ collected data from more than 1000 patients at 45 US hospitals or outpatient infection clinics from January 1, 2012 to March 31, 2013. Patients included in the study were 18 years of age or older, and had a confirmed diagnosis of bloodstream infection or endocarditis.

RESULTS

TOUR™ data indicated that Telavancin was well-tolerated, with a safety profile consistent with previous studies. The study also showed that patients treated with Telavancin had improved clinical outcomes compared to historical controls.

CONCLUSIONS

The results of the TOUR™ study support the use of Telavancin for the treatment of bacteremia and endocarditis, and highlight the importance of real-world data in evaluating the efficacy and safety of new treatments.

REFERENCES


ACKNOWLEDGMENTS

The TOUR™ study was supported by TheravanceBiopharma, Inc. This non-interventional study was conducted by Matt Goldhammer, Gilead Sciences, Inc. and TheravanceBiopharma, Inc. under a research agreement with Theravance Biopharma, Inc. and Funded by Theravance Biopharma, Inc.

Presented at the 2017 IDWeek-Meeting, San Diego, CA, October 4-8, 2017.